Sensei Biotherapeutics (NASDAQ:FTH) Trading 7.4% Higher – Here’s What Happened

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) shot up 7.4% during trading on Thursday . The company traded as high as $38.41 and last traded at $38.7930. 40,523 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 214,469 shares. The stock had previously closed at $36.12.

Analyst Ratings Changes

Several equities research analysts recently commented on FTH shares. Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They set an “outperform” rating and a $57.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. TD Cowen began coverage on Sensei Biotherapeutics in a report on Wednesday. They set a “buy” rating on the stock. Wall Street Zen upgraded Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Sensei Biotherapeutics in a report on Thursday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Stock Performance

The stock’s 50-day simple moving average is $31.34. The firm has a market cap of $967.45 million, a PE ratio of -0.26 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. Equities research analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current fiscal year.

Insider Activity

In related news, CFO Brian C. Stephenson purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were purchased at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the acquisition, the chief financial officer directly owned 46,688 shares in the company, valued at $1,097,168. This represents a 11.99% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was bought at an average price of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 49,494 shares of company stock valued at $1,188,822 in the last quarter. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its stake in shares of Sensei Biotherapeutics by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after purchasing an additional 1,100 shares during the last quarter. Citadel Advisors LLC purchased a new position in Sensei Biotherapeutics in the 2nd quarter valued at $307,000. Bank of America Corp DE grew its position in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Sensei Biotherapeutics in the 2nd quarter valued at $3,610,000. Finally, Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.